Consistently, the follistatin-myostatin axis has been identified as a target to ameliorate MDs; indeed, myostatin blockade at early stages of the disease provides a beneficial effect in both mdx and α-SG–deficient mice [129,130]. The gene discussed is MSTN; the disease is myelodysplastic syndrome.